Aberrant Methylation of PCDH10 Predicts Worse Biochemical Recurrence-Free Survival in Patients with Prostate Cancer After Radical Prostatectomy
Abstract
Our results indicate that PCDH10 methylation in prostate cancer tissue is an independent prognostic biomarker of worse BCR-free survival of patients with prostate cancer after radical prostatectomy.
Metrics
Citation History
Topics
Related Documents
TWIST overexpression predicts biochemical recurrence-free survival in prostate cancer patients treated with radical prostatectomy
Sami RaatikainenS. AaltomaaJorma J. PalvimoVesa KärjäYlermi Soini
Conditional biochemical recurrence-free survival after radical prostatectomy in patients with high-risk prostate cancer
Sung‐Woo ParkDae Sung HwangWon Hoon SongJong Kil NamHyun Jung LeeMoon Kee Chung
A Novel Gene Signature-Based Model Predicts Biochemical Recurrence-Free Survival in Prostate Cancer Patients after Radical Prostatectomy
Run ShiXuanwen BaoJoachim WeischenfeldtChristian SchaeferPaul RogowskiNina-Sophie Schmidt-HegemannKristian UngerKirsten LauberXuanbin WangAlexander BüchnerChristian G. StiefThorsten SchlommClaus BelkaMinglun Li
PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy
Emily Eva HolmesDiane GoltzVerena SailerMaria JungSebastian MellerBarbara UhlJörn DietrichMagda RöhlerJörg EllingerGlen KristiansenDimo Dietrich
Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer
Jean‐Baptiste BeauvalM. RoumiguiéThomas FilleronT. BenoitAlexandre de la TailleBernard MalavaudLaurent SalomonM. SouliéGuillaume Ploussard